サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1790499

エルレアーダの市場規模、シェア、動向分析レポート：タイプ別、流通チャネル別、地域別、セグメント別予測、2025年～2033年

Erleada Market Size, Share & Trends Analysis Report By Type (Branded, Generic), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
エルレアーダの市場規模、シェア、動向分析レポート：タイプ別、流通チャネル別、地域別、セグメント別予測、2025年～2033年
出版日: 2025年07月08日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アーリーダ市場のサマリー

アーリーダの世界市場規模は2024年に29億9,900万米ドルと推計され、2033年には61億6,600万米ドルに達すると予測され、2025年から2033年までのCAGRは7.99%で成長すると予測されます。アーリーダ業界は、転移性去勢抵抗性前立腺がん（mCRPC）の治療成績を向上させるための併用療法への取り組みによってますます形成されつつあります。

2027年に終了予定のNCT02257736のような第3相臨床試験では、アパルタミドを酢酸アビラテロンやプレドニゾンと併用して評価し、相乗効果の確立と適応拡大の可能性を探っています。SPARTAN試験の転移リスク70％減少（HR 0.28）のような臨床データを活用することで、利害関係者は支払者との交渉を強化し、市場牽引力を維持することができます。併用療法を重視することで、2025年3月にUSFDAの承認を取得したザイダスライフサイエンス社のアパルタミド錠のような新興ジェネリック医薬品に対するアーリーダの立場が強化され、アーリーダの市場独占権が脅かされることになります。ジョンソンエンドジョンソンの特許は2038年まで特定の製剤をカバーしており、法的保護を提供しているが、訴訟の可能性は依然として懸念材料となっています。

市場は、特にメディケアのような米国の支払者が、長期的なベネフィットが証明された治療法を好む、バリューベースケアの採用拡大に影響を受けています。TITANによる33%の死亡リスク低下（HR 0.67）を含むアーリーダの臨床エビデンスは、メディケアアドバンテージプランが2024年に代替療法と比較してnmCRPC患者の入院を10%減少させると報告しているように、実世界にインパクトを与えています。利害関係者は、費用対効果を実証するための実臨床エビデンスを作成し、アパルタミドの投与に関する医療従事者教育に投資することで、市場の回復力を高め、普及を促進し、ジェネリック医薬品の競合による影響を緩和することができます。

アーリーダ業界は、米国予防サービス専門委員会（U.S. Preventive Services Task Force）のようなイニシアチブに支えられた早期前立腺がん検診に対する熱心な認識によって、診断率の向上と対象患者の拡大という恩恵を受けています。この動向は、アーリーダの標的メカニズムと相まって、精密医療へのシフトと合致し、アンメットニーズに対応する機会を提供します。例えば、2023年に承認された1日1回240mgの錠剤は、患者のコンプライアンスを向上させ、アーリーダの競争力を強化するものです。利害関係者は、進化する治療パラダイムの中で市場でのリーダーシップを維持するために、こうした進歩を活用することに注力すべきです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 アーリーダ市場の変数、動向、範囲

  • 市場系統の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 業界分析- ポーターのファイブフォース分析
    • PESTLE分析
    • パイプライン分析
    • 特許満了分析
    • 価格分析

第4章 アーリーダ市場：タイプビジネス分析

  • タイプ別市場シェア、2024年と2033年
  • タイプセグメントダッシュボード
  • 市場規模、予測、動向分析（タイプ別、2021～2033年）
  • ブランド
  • ジェネリック

第5章 アーリーダ市場：流通チャネルビジネス分析

  • 流通チャネル市場シェア、2024年および2033年
  • 流通チャネルセグメントダッシュボード
  • 市場規模、予測、動向分析（流通チャネル別、2021～2033年）
  • 病院薬局
  • 小売薬局
  • その他

第6章 アーリーダ市場：地域推定・動向分析

  • 地域別市場シェア分析、2024年および2033年
  • 地域市場ダッシュボード
  • 市場規模と予測動向分析、2021～2033年
  • 北米
    • 国別、2021年～2033年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東およびアフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Janssen Biotech, Inc.
    • Zydus Lifesciences
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Erleada market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 5 Global Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6 North America Erleada market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 8 North America Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9 U.S. Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 10 U.S. Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 Canada Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 12 Canada Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13 Mexico Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 14 Mexico Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15 Europe Erleada market, by country, 2021 - 2033 (USD Million)
  • Table 16 Europe Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 17 Europe Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 18 UK Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 19 UK Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Germany Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 21 Germany Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22 France Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 23 France Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 Italy Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 25 Italy Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 26 Spain Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 27 Spain Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28 Norway Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 29 Norway Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 Denmark Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 31 Denmark Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32 Sweden Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 33 Sweden Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific Erleada market, by country, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 36 Asia Pacific Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 37 Japan Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 38 Japan Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 China Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 40 China Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41 India Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 42 India Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43 Australia Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 44 Australia Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 South Korea Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 46 South Korea Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47 Thailand Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 48 Thailand Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 49 Latin America Erleada market, by country, 2021 - 2033 (USD Million)
  • Table 50 Latin America Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 51 Latin America Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Brazil Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 53 Brazil Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54 Argentina Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 55 Argentina Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa Erleada market, by country, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 58 Middle East & Africa Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59 South Africa Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 60 South Africa Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 62 Saudi Arabia Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 63 UAE Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 64 UAE Erleada market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65 Kuwait Erleada market, by Type, 2021 - 2033 (USD Million)
  • Table 66 Kuwait Erleada market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Erleada market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Erleada market dynamics
  • Fig. 12 Erleada market: Porter's five forces analysis
  • Fig. 13 Erleada market: PESTLE analysis
  • Fig. 14 Type market, 2021 - 2033 (USD Million)
  • Fig. 15 Branded market, 2021 - 2033 (USD Million)
  • Fig. 16 Generic market, 2021 - 2033 (USD Million)
  • Fig. 17 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 18 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 19 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 20 Others market, 2021 - 2033 (USD Million)
  • Fig. 21 Erleada market revenue, by region
  • Fig. 22 Regional marketplace: Key takeaways
  • Fig. 23 North America Erleada market, 2021 - 2033 (USD Million)
  • Fig. 24 US country dynamics
  • Fig. 25 US Erleada market, 2021 - 2033 (USD Million)
  • Fig. 26 Canada country dynamics
  • Fig. 27 Canada Erleada market, 2021 - 2033 (USD Million)
  • Fig. 28 Mexico country dynamics
  • Fig. 29 Mexico Erleada market, 2021 - 2033 (USD Million)
  • Fig. 30 Europe Erleada market, 2021 - 2033 (USD Million)
  • Fig. 31 UK country dynamics
  • Fig. 32 UK Erleada market, 2021 - 2033 (USD Million)
  • Fig. 33 Germany country dynamics
  • Fig. 34 Germany Erleada market, 2021 - 2033 (USD Million)
  • Fig. 35 France country dynamics
  • Fig. 36 France Erleada market, 2021 - 2033 (USD Million)
  • Fig. 37 Italy country dynamics
  • Fig. 38 Italy Erleada market, 2021 - 2033 (USD Million)
  • Fig. 39 Spain country dynamics
  • Fig. 40 Spain Erleada market, 2021 - 2033 (USD Million)
  • Fig. 41 Norway country dynamics
  • Fig. 42 Norway Erleada market, 2021 - 2033 (USD Million)
  • Fig. 43 Sweden country dynamics
  • Fig. 44 Sweden Erleada market, 2021 - 2033 (USD Million)
  • Fig. 45 Denmark country dynamics
  • Fig. 46 Denmark Erleada market, 2021 - 2033 (USD Million)
  • Fig. 47 Asia Pacific Erleada market, 2021 - 2033 (USD Million)
  • Fig. 48 Japan country dynamics
  • Fig. 49 Japan Erleada market, 2021 - 2033 (USD Million)
  • Fig. 50 China country dynamics
  • Fig. 51 China Erleada market, 2021 - 2033 (USD Million)
  • Fig. 52 India country dynamics
  • Fig. 53 India Erleada market, 2021 - 2033 (USD Million)
  • Fig. 54 Australia country dynamics
  • Fig. 55 Australia Erleada market, 2021 - 2033 (USD Million)
  • Fig. 56 South Korea country dynamics
  • Fig. 57 South Korea Erleada market, 2021 - 2033 (USD Million)
  • Fig. 58 Thailand country dynamics
  • Fig. 59 Thailand Erleada market, 2021 - 2033 (USD Million)
  • Fig. 60 Latin America Erleada market, 2021 - 2033 (USD Million)
  • Fig. 61 Brazil country dynamics
  • Fig. 62 Brazil Erleada market, 2021 - 2033 (USD Million)
  • Fig. 63 Argentina country dynamics
  • Fig. 64 Argentina Erleada market, 2021 - 2033 (USD Million)
  • Fig. 65 MEA Erleada market, 2021 - 2033 (USD Million)
  • Fig. 66 South Africa country dynamics
  • Fig. 67 South Africa Erleada market, 2021 - 2033 (USD Million)
  • Fig. 68 Saudi Arabia country dynamics
  • Fig. 69 Saudi Arabia Erleada market, 2021 - 2033 (USD Million)
  • Fig. 70 UAE country dynamics
  • Fig. 71 UAE Erleada market, 2021 - 2033 (USD Million)
  • Fig. 72 Kuwait country dynamics
  • Fig. 73 Kuwait Erleada market, 2021 - 2033 (USD Million)
  • Fig. 74 Company categorization
  • Fig. 75 Company market position analysis
  • Fig. 76 Strategic framework
目次
Product Code: GVR-4-68040-662-9

Erleada Market Summary

The global erleada market size was estimated at USD 2,999 million in 2024 and is projected to reach USD 6,166 million by 2033, growing at a CAGR of 7.99% from 2025 to 2033. The erleada industry is increasingly shaped by the push toward combination therapies to enhance treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC).

Phase 3 trials, such as NCT02257736, set to conclude in 2027, are evaluating Apalutamide alongside Abiraterone acetate and Prednisone to establish synergistic effects and potentially expand indications. By leveraging clinical data, like the SPARTAN trial's 70% reduction in metastasis risk (HR 0.28), stakeholders can strengthen payer negotiations and maintain market traction. The emphasis on combination therapies strengthens Erleada's position against emerging generics, like Zydus Lifesciences' Apalutamide Tablets, which received USFDA approval in March 2025, threatening Erleada's market exclusivity. Johnson & Johnson's patents, covering specific formulations until 2038, offer legal protection, but the potential for litigation remains a concern.

The market is influenced by the growing adoption of value-based care, particularly among U.S. payers like Medicare, who favor therapies with proven long-term benefits. Erleada's clinical evidence, including TITAN's 33% mortality risk reduction (HR 0.67), has driven real-world impact, with Medicare Advantage plans reporting a 10% reduction in nmCRPC patient hospitalizations in 2024 compared to alternatives. Stakeholders can enhance market resilience by generating real-world evidence to demonstrate cost-effectiveness and investing in healthcare provider education on Apalutamide's administration to boost adoption and mitigate the impact of generic competition.

The erleada industry benefits from keen awareness of early prostate cancer screening, supported by initiatives like those from the U.S. Preventive Services Task Force, which have increased diagnosis rates and expanded the eligible patient pool. This trend, coupled with Erleada's targeted mechanism, aligns with the shift toward precision medicine, offering opportunities to address unmet needs. For instance, the 2023 approval of a 240 mg once-daily tablet improved patient compliance, reinforcing Erleada's competitive positioning. Stakeholders should focus on leveraging these advancements to maintain market leadership amidst evolving treatment paradigms.

Global Erleada Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global erleada market report based on type, distribution channel, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Branded
  • Generic
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Erleada Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Erleada Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Branded
    • 4.4.1. Branded Market, 2021 - 2033 (USD Million)
  • 4.5. Generic
    • 4.5.1. Generic Market, 2021 - 2033 (USD Million)

Chapter 5. Erleada Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Erleada Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Erleada Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. Canada Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Brazil Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. Argentina Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Erleada Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Janssen Biotech, Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Zydus Lifesciences
      • 7.6.1.1. Overview
      • 7.6.1.2. Financial Performance
      • 7.6.1.3. Product Benchmarking
      • 7.6.1.4. Strategic Initiatives